<p>香港，2026 年 5 月 13 日 -（ACN Newswire）- SinoMab BioScience Limited（“SinoMab” 或 “公司”，连同其子公司，统称为 “集团”；股票代码：03681.HK）欣然宣布，公司执行董事、董事长兼首席执行官梁水安博士受邀作为特邀嘉宾在 2026 年伦敦生命弧转化科学峰会上发表演讲。作为全球转化医学领域最具影响力的活动之一，峰会汇聚了来自全球的顶尖科学家、临床医生、行业领袖、政策制定者和机构投资者。在活动期间，梁水安博士发表了主题演讲，系统阐述了 SinoMab 在自身免疫疾病研发方面的战略以及其核心管线的最新临床进展，并与国际同行进行了深入对话。</p>
<p>本次峰会由英国著名医学研究慈善机构生命弧主办，致力于弥合早期科学研究与现实临床应用之间的差距，在解决罕见疾病和广泛未满足的医疗需求方面具有深厚的专业知识和影响力。今年的峰会聚焦于如何通过推进新型治疗模式、转变临床实践、塑造健康政策和推动商业创新，加速从实验室发现到患者获取的整个过程。与会者就抗体药物、基因治疗和细胞治疗等前沿领域进行了跨学科讨论，探索突破转化医学核心瓶颈的解决方案，推动行业、学术界、研究和临床领域的综合发展。梁水安博士受邀参加这一高端活动，标志着国际权威机构对 SinoMab 在免疫治疗领域创新努力的高度认可。</p>
<p>在他的主题演讲中，梁水安博士分析了全球自身免疫疾病治疗研发的现状和面临的挑战，并详细阐述了 SinoMab 以 “首创” 和 “最佳” 药物开发为基础的差异化创新框架。他详细介绍了公司的旗舰人源化单克隆抗体 SM17，该抗体靶向白细胞介素-25（IL-25）受体。SM17 通过精确结合 IL-25 受体，这一调节 2 型免疫反应的关键上游警报分子，阻断了炎症级联反应的源头。它在多种炎症和免疫介导的疾病中具有广泛的治疗潜力，包括特应性皮炎（AD）、炎症性肠病（IBD）、哮喘、慢性鼻窦炎伴鼻息肉和特发性肺纤维化。梁博士分享了 SM17 最近取得的一系列里程碑式进展。在 AD 治疗领域，1b 期临床数据展示了卓越的治疗效果。在高剂量组中，91.7% 的患者报告根据 NRS-4 量表显著缓解瘙痒，75% 实现了 EASI 75 皮损改善，41.7% 达到了 AD 症状的完全或近完全清除（IGA 0/1）。这些临床结果优于现有的 IL-4/IL-13 靶向单克隆抗体，同时该产品的安全性也优于 JAK 抑制剂。在这些令人鼓舞的结果基础上，SM17 针对中重度 AD 的二期临床试验于 2026 年 3 月 31 日在中国大陆完成首位患者给药。该试验计划招募约 210 名参与者，预计在 2026 年下半年完成全部招募，顶线临床数据预计在 2027 年上半年发布。在给药便利性方面，SM17 皮下制剂的 I 期桥接研究于 2026 年 3 月 25 日发布了积极的顶线结果。来自 30 名健康志愿者的数据确认了皮下注射途径的安全性和稳定的药代动力学表现。仅报告了一例轻度 1 级注射部位皮疹，且在未干预的情况下自愈，且验证了良好的绝对生物利用度，为开发更便捷的皮下给药方案奠定了坚实基础。此外，SM17 已成功扩展其治疗适应症至 IBD。其针对克罗恩病和溃疡性结肠炎的研究性新药（IND）申请于 2026 年 2 月 24 日获得中国国家药品监督管理局（NMPA）的正式批准。相关的桥接研究在同月完成，为直接进入二期临床开发铺平了道路。梁博士还强调了公司的创新早期管线，包括抗 CGC 抗体（首创人源化抗-γc 抗体），该抗体在治疗如脱发斑和白癜风等自身免疫疾病方面显示出潜力，计划于 2026 年第四季度提交 IND 申请。针对 RANKL 和骨保护素的创新双特异性抗体在骨相关疾病的临床前研究中显示出优于市场疗法的疗效，计划于 2027 年上半年提交 IND 申请。梁博士强调，通过关注创新和未开发的药物靶点，SinoMab 建立了协同的产品组合，努力为全球患者提供更安全、更有效和更易获取的突破性疗法。</p>
<p>受邀参加此次 LifeArc 转化科学峰会，不仅是国际知名机构对 SinoMab 在抗体研发方面创新优势和探索工作的高度认可，也是深化我们全球合作伙伴关系的关键机会。通过与领先科学家、临床研究人员及跨国制药公司高管的深入交流，SinoMab 进一步扩展了其国际学术网络和潜在合作渠道，为未来的技术引进、共同开发、外部授权和商业化奠定了坚实基础。梁水安博士表示，公司将继续专注于解决自身免疫疾病中的未满足临床需求。它将加速核心管线资产如 SM17 的全球多中心临床开发，同时积极探索人工智能及其他新技术如何促进新靶点的发现。此外，借助与中山大学香港高级研究院等机构的战略合作，SinoMab 旨在加强从实验室到临床的转化能力。展望未来，SinoMab 将抓住中国生物技术外部授权市场的快速增长机会，坚守差异化的全球创新路径，积极寻求与全球合作伙伴的多元化合作模式，加速将创新疗法带给全球患者，同时为股东创造长期价值。</p>
<p>关于 SinoMab 生物科学有限公司</p>
<p>SinoMab 生物科学有限公司（股票代码：03681.HK）是首创和潜在最佳治疗抗体药物研发的先锋，专注于自身免疫疾病、神经退行性疾病及其他严重疾病，致力于满足未满足的医疗需求。SinoMab 一直专注于开发针对新靶点的治疗性抗体，并采用创新机制，旨在实现现有疗法效果有限领域的差异化临床结果。其丰富的研发管线包括：SM17，在治疗特应性皮炎（AD）方面表现出卓越的抗瘙痒效果、皮肤清除率和安全性，且在哮喘和特发性肺纤维化（IPF）方面具有潜在应用；其旗舰抗 CD22 抗体 Suciraslimab，已在类风湿关节炎（RA）中临床验证有效性，目前正在进行系统性红斑狼疮（SLE）和阿尔茨海默病的临床评估；另一种创新的抗 CGC（共同伽马链）单克隆抗体，正在准备进入治疗脱发斑和白癜风的临床研究；以及由 SinoMab 开发的一种双特异性单克隆抗体，能够同时刺激骨生长并抑制骨流失，用于治疗骨质疏松症。以突破性疗效为核心追求，SinoMab 不断重新定义患者护理标准，并在突破性疗法领域保持领先地位。</p>
<p>本新闻稿由 Zhenzhuo Group 代表 SinoMab 生物科学有限公司发布。</p>
<p>投资者和媒体咨询</p>
<p>联系人：</p>
<p>Bunny Lee</p>
<p>Nomia Zhou</p>
<p>Qiuyan Deng</p>
<p>电话：（852）5316 9995</p>
<p>电子邮件：ir_sinomab@zhenzhuoglobal.com</p>
<p>来源：SinoMab 生物科学有限公司</p>
<p>版权 2026 ACN Newswire。保留所有权利。</p>

中国抗体-B

<p>中国抗体-B 有限公司宣布，其执行董事兼首席执行官梁水安博士受邀在 2026 年伦敦 LifeArc 转化科学峰会上发表演讲。他就公司的自身免疫疾病研发策略进行了主题演讲，重点介绍了其旗舰药物 SM17 的进展。此次峰会聚焦于科学研究与临床应用的结合，讨论了抗体药物和基因治疗的进展。梁博士的邀请反映了国际社会对中国抗体-B 在免疫治疗领域创新努力的认可，并为加强全球合作提供了机会</p>

<p>HONG KONG, May 13, 2026 - (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group'; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief Executive Officer of the Company, was invited as a special guest to present at the 2026 LifeArc Translational Science Summit in London,UK. As one of the most influential global events in translational medicine, the summit brought together top scientists, practicing clinicians, industry leaders, policymakers and institutional investors from across the globe. During the event, Dr. Shui On Leung delivered a keynote speech, systematically outlining SinoMab's R&amp;D strategies for autoimmune diseases and the latest clinical progress of its core pipeline, while engaging in in-depth dialogues with international peers.</p>
<div class="lb-trans"><p>香港，2026 年 5 月 13 日 -（ACN Newswire）- SinoMab BioScience Limited（“SinoMab” 或 “公司”，连同其子公司，统称为 “集团”；股票代码：03681.HK）欣然宣布，公司执行董事、董事长兼首席执行官梁水安博士受邀作为特邀嘉宾在 2026 年伦敦生命弧转化科学峰会上发表演讲。作为全球转化医学领域最具影响力的活动之一，峰会汇聚了来自全球的顶尖科学家、临床医生、行业领袖、政策制定者和机构投资者。在活动期间，梁水安博士发表了主题演讲，系统阐述了 SinoMab 在自身免疫疾病研发方面的战略以及其核心管线的最新临床进展，并与国际同行进行了深入对话。</p>
</div><p>Hosted by LifeArc, a prestigious UK medical research charity, the annual summit is committed to bridging early-stage scientific research and real-world clinical application, with profound expertise and influence in addressing rare diseases and wide-ranging unmet medical needs. This year's summit centered on how translational research can accelerate the entire journey from laboratory discoveries to patient access, by advancing novel treatment modalities, transforming clinical practice, shaping health policies and driving commercial innovation. Attendees held interdisciplinary discussions on cutting-edge areas including antibody drugs, gene therapy and cell therapy, exploring solutions to break through core bottlenecks in translational medicine and boost integrated development across industry, academia, research and clinical sectors. Dr. Shui On Leung's invitation to this high-profile event marks high recognition from leading international authorities of SinoMab's innovative efforts in immunotherapy.</p>
<div class="lb-trans"><p>本次峰会由英国著名医学研究慈善机构生命弧主办，致力于弥合早期科学研究与现实临床应用之间的差距，在解决罕见疾病和广泛未满足的医疗需求方面具有深厚的专业知识和影响力。今年的峰会聚焦于如何通过推进新型治疗模式、转变临床实践、塑造健康政策和推动商业创新，加速从实验室发现到患者获取的整个过程。与会者就抗体药物、基因治疗和细胞治疗等前沿领域进行了跨学科讨论，探索突破转化医学核心瓶颈的解决方案，推动行业、学术界、研究和临床领域的综合发展。梁水安博士受邀参加这一高端活动，标志着国际权威机构对 SinoMab 在免疫治疗领域创新努力的高度认可。</p>
</div><p>In his keynote address, Dr. Shui On Leung analyzed the current landscape and prevailing challenges in global R&amp;D for autoimmune disease therapeutics, and elaborated on SinoMab's differentiated innovation framework anchored in 'First-in-Class' and 'Best-in-Class' drug development. He gave a detailed introduction to SM17, the Company's flagship humanized monoclonal antibody targeting the interleukin-25 (IL-25) receptor. By precisely binding to IL-25 receptor, a key upstream alarmin molecule regulating type 2 immune responses, SM17 blocks inflammatory cascade reactions at the source. It holds broad therapeutic potential for a spectrum of inflammatory and immune-mediated disorders, including atopic dermatitis (AD), inflammatory bowel disease (IBD), asthma, chronic rhinosinusitis with nasal polyps, and idiopathic pulmonary fibrosis. Dr. Leung shared a series of landmark milestones achieved by SM17 recently. In the AD treatment landscape, Phase 1b clinical data demonstrated outstanding therapeutic efficacy. In the high-dose cohort, 91.7% of patients reported significant itch relief measured by the NRS-4 scale, 75% achieved EASI 75 skin lesion improvement, and 41.7% attained complete or near-complete clearance of AD symptoms (IGA 0/1). Such clinical outcomes outperform existing IL-4/IL-13 targeted monoclonal antibodies, while the product also boasts a more favorable safety profile compared with JAK inhibitors. Building on these promising results, the Phase II clinical trial of SM17 for moderate-to-severe AD completed first patient dosing in mainland China on 31 March 2026. The trial plans to enroll approximately 210 participants, with full enrollment expected in the second half of 2026 and topline clinical data slated for release in the first half of 2027. In terms of administration convenience, the Phase I bridging study of SM17 subcutaneous formulation released positive topline results on 25 March 2026. Data from 30 healthy volunteers confirmed the subcutaneous injection route with satisfactory safety and stable pharmacokinetic performance. Only one mild Grade 1 injection site rash was reported, which resolved spontaneously without intervention, and robust absolute bioavailability was validated, laying a solid foundation for the development of more user-friendly subcutaneous dosing regimens. Furthermore, SM17 has successfully expanded its therapeutic indications to IBD. Its Investigational New Drug (IND) application for Crohn's disease and ulcerative colitis was officially approved by China's National Medical Products Administration (NMPA) on 24 February 2026. Relevant bridging studies were finalized in the same month, paving the way for direct progression to Phase II clinical development. Dr. Leung also highlighted the Company's innovative early-stage pipeline, including the anti-CGC antibody (a first-in-class humanized anti-γc antibody), which has demonstrated potential in the treatment of autoimmune diseases such as alopecia areata and vitiligo, with an IND submission planned for the fourth quarter of 2026. A novel bispecific antibody targeting RANKL and sclerostin has demonstrated superior efficacy over marketed therapies in preclinical studies for bone-related disorders, and its IND filing is targeted for the first half of 2027. Dr. Leung emphasized that by focusing on innovative and untapped drug targets, SinoMab has built a synergistic product portfolio, striving to deliver safer, more effective and more accessible breakthrough therapies for patients worldwide.</p>
<div class="lb-trans"><p>在他的主题演讲中，梁水安博士分析了全球自身免疫疾病治疗研发的现状和面临的挑战，并详细阐述了 SinoMab 以 “首创” 和 “最佳” 药物开发为基础的差异化创新框架。他详细介绍了公司的旗舰人源化单克隆抗体 SM17，该抗体靶向白细胞介素-25（IL-25）受体。SM17 通过精确结合 IL-25 受体，这一调节 2 型免疫反应的关键上游警报分子，阻断了炎症级联反应的源头。它在多种炎症和免疫介导的疾病中具有广泛的治疗潜力，包括特应性皮炎（AD）、炎症性肠病（IBD）、哮喘、慢性鼻窦炎伴鼻息肉和特发性肺纤维化。梁博士分享了 SM17 最近取得的一系列里程碑式进展。在 AD 治疗领域，1b 期临床数据展示了卓越的治疗效果。在高剂量组中，91.7% 的患者报告根据 NRS-4 量表显著缓解瘙痒，75% 实现了 EASI 75 皮损改善，41.7% 达到了 AD 症状的完全或近完全清除（IGA 0/1）。这些临床结果优于现有的 IL-4/IL-13 靶向单克隆抗体，同时该产品的安全性也优于 JAK 抑制剂。在这些令人鼓舞的结果基础上，SM17 针对中重度 AD 的二期临床试验于 2026 年 3 月 31 日在中国大陆完成首位患者给药。该试验计划招募约 210 名参与者，预计在 2026 年下半年完成全部招募，顶线临床数据预计在 2027 年上半年发布。在给药便利性方面，SM17 皮下制剂的 I 期桥接研究于 2026 年 3 月 25 日发布了积极的顶线结果。来自 30 名健康志愿者的数据确认了皮下注射途径的安全性和稳定的药代动力学表现。仅报告了一例轻度 1 级注射部位皮疹，且在未干预的情况下自愈，且验证了良好的绝对生物利用度，为开发更便捷的皮下给药方案奠定了坚实基础。此外，SM17 已成功扩展其治疗适应症至 IBD。其针对克罗恩病和溃疡性结肠炎的研究性新药（IND）申请于 2026 年 2 月 24 日获得中国国家药品监督管理局（NMPA）的正式批准。相关的桥接研究在同月完成，为直接进入二期临床开发铺平了道路。梁博士还强调了公司的创新早期管线，包括抗 CGC 抗体（首创人源化抗-γc 抗体），该抗体在治疗如脱发斑和白癜风等自身免疫疾病方面显示出潜力，计划于 2026 年第四季度提交 IND 申请。针对 RANKL 和骨保护素的创新双特异性抗体在骨相关疾病的临床前研究中显示出优于市场疗法的疗效，计划于 2027 年上半年提交 IND 申请。梁博士强调，通过关注创新和未开发的药物靶点，SinoMab 建立了协同的产品组合，努力为全球患者提供更安全、更有效和更易获取的突破性疗法。</p>
</div><p>Being invited to this LifeArc Translational Science Summit is not only a strong recognition from a respected international institution of SinoMab's innovative edge and exploratory work in antibody R&amp;D, but also a key opportunity to deepen our global partnerships. Through in-depth exchanges with leading scientists, clinical researchers and senior executives of multinational pharmaceutical companies, SinoMab has further expanded its international academic network and potential partnership channels, laying a solid foundation for future technology in-licensing, co-development, out-licensing and commercialization. Dr. Shui On Leung stated that the Company will remains focused on addressing unmet clinical needs in autoimmune diseases. It will accelerate global multi-center clinical development of core pipeline assets such as SM17, while actively exploring how AI and other new technologies can boost novel target discovery. In addition, drawing on strategic collaborations with institutions like the Sun Yat-sen University Institute of Advanced Studies Hong Kong, SinoMab aims to strengthen its translational capabilities from bench to bedside. Looking ahead, SinoMab will seize the rapid growth opportunities in China's biotech out-licensing market, stay true to a differentiated global innovation path, and actively pursue diversified collaboration models with global partners, and accelerate the delivery of innovative therapies to patients worldwide, while creating long-term value for shareholders.</p>
<div class="lb-trans"><p>受邀参加此次 LifeArc 转化科学峰会，不仅是国际知名机构对 SinoMab 在抗体研发方面创新优势和探索工作的高度认可，也是深化我们全球合作伙伴关系的关键机会。通过与领先科学家、临床研究人员及跨国制药公司高管的深入交流，SinoMab 进一步扩展了其国际学术网络和潜在合作渠道，为未来的技术引进、共同开发、外部授权和商业化奠定了坚实基础。梁水安博士表示，公司将继续专注于解决自身免疫疾病中的未满足临床需求。它将加速核心管线资产如 SM17 的全球多中心临床开发，同时积极探索人工智能及其他新技术如何促进新靶点的发现。此外，借助与中山大学香港高级研究院等机构的战略合作，SinoMab 旨在加强从实验室到临床的转化能力。展望未来，SinoMab 将抓住中国生物技术外部授权市场的快速增长机会，坚守差异化的全球创新路径，积极寻求与全球合作伙伴的多元化合作模式，加速将创新疗法带给全球患者，同时为股东创造长期价值。</p>
</div><p>About SinoMab BioScience Limited</p>
<div class="lb-trans"><p>关于 SinoMab 生物科学有限公司</p>
</div><p>SinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&amp;D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies.</p>
<div class="lb-trans"><p>SinoMab 生物科学有限公司（股票代码：03681.HK）是首创和潜在最佳治疗抗体药物研发的先锋，专注于自身免疫疾病、神经退行性疾病及其他严重疾病，致力于满足未满足的医疗需求。SinoMab 一直专注于开发针对新靶点的治疗性抗体，并采用创新机制，旨在实现现有疗法效果有限领域的差异化临床结果。其丰富的研发管线包括：SM17，在治疗特应性皮炎（AD）方面表现出卓越的抗瘙痒效果、皮肤清除率和安全性，且在哮喘和特发性肺纤维化（IPF）方面具有潜在应用；其旗舰抗 CD22 抗体 Suciraslimab，已在类风湿关节炎（RA）中临床验证有效性，目前正在进行系统性红斑狼疮（SLE）和阿尔茨海默病的临床评估；另一种创新的抗 CGC（共同伽马链）单克隆抗体，正在准备进入治疗脱发斑和白癜风的临床研究；以及由 SinoMab 开发的一种双特异性单克隆抗体，能够同时刺激骨生长并抑制骨流失，用于治疗骨质疏松症。以突破性疗效为核心追求，SinoMab 不断重新定义患者护理标准，并在突破性疗法领域保持领先地位。</p>
</div><p>This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.</p>
<div class="lb-trans"><p>本新闻稿由 Zhenzhuo Group 代表 SinoMab 生物科学有限公司发布。</p>
</div><p>Investor and Media Inquiries</p>
<div class="lb-trans"><p>投资者和媒体咨询</p>
</div><p>Contact Person:</p>
<div class="lb-trans"><p>联系人：</p>
</div><p>Bunny Lee</p>
<div class="lb-trans"><p>Bunny Lee</p>
</div><p>Nomia Zhou</p>
<div class="lb-trans"><p>Nomia Zhou</p>
</div><p>Qiuyan Deng</p>
<div class="lb-trans"><p>Qiuyan Deng</p>
</div><p>Phone: (852) 5316 9995</p>
<div class="lb-trans"><p>电话：（852）5316 9995</p>
</div><p>Email: ir_sinomab@zhenzhuoglobal.com</p>
<div class="lb-trans"><p>电子邮件：ir_sinomab@zhenzhuoglobal.com</p>
</div><p>Source: SinoMab BioScience Limited</p>
<div class="lb-trans"><p>来源：SinoMab 生物科学有限公司</p>
</div><p>Copyright 2026 ACN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版权 2026 ACN Newswire。保留所有权利。</p>
</div>

梁水安博士受邀参加 2026 年在英国举行的 LifeArc 转化科学峰会